M. Nussenzweig

Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose

This study shows that a third mRNA vaccine dose increases the potency and breadth of SARS-CoV-2 neutralizing antibodies, particularly against the Omicron variant, through the expansion and evolution of memory B cells.

Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer

This study identifies two antibodies from immunized macaques that neutralize HIV-1 by targeting the CD4-binding site on an occluded-open Env trimer conformation.

Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing

This study uses Q4PCR to measure longitudinal changes in HIV-1 latent reservoirs, finding that intact proviruses decay faster than defective ones and show increased clonal expansion over time.

Inflammasome activation in infected macrophages drives COVID-19 pathology

This study shows SARS-CoV-2 infection of human macrophages drives COVID-19 pathology through inflammasome activation, leading to inflammation and pyroptosis, but also enabling viral release.

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

This study examines how somatic mutations in SARS-CoV-2 antibodies affect their neutralization potency, breadth, and resistance to escape mutations across six antibody lineages.

Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants

This paper isolates and characterizes nanobodies from camelids and engineered mice that neutralize SARS-CoV-2 variants through conserved epitopes and multimeric avidity.